Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
16:51:58 EDT Sun 28 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:LGND from 2023-04-27 to 2024-04-26 - 39 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-23 08:31U:LGNDNews ReleaseLigand to Report First Quarter 2024 Financial Results on May 7, 2024
2024-04-08 08:15U:LGNDNews ReleaseLigand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
2024-04-03 09:00U:LGNDNews ReleaseLigand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI(TM)
2024-03-05 16:01U:LGNDNews ReleaseLigand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference
2024-03-04 08:00U:LGNDNews ReleaseLigand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-27 07:00U:LGNDNews ReleaseLigand Reports Fourth Quarter and Full Year 2023 Financial Results
2024-02-22 16:01U:LGNDNews ReleaseLigand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa(TM)
2024-02-16 08:00U:LGNDNews ReleaseLigand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires
2024-02-13 16:01U:LGNDNews ReleaseLigand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
2024-02-01 17:00U:LGNDNews ReleaseLigand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-01-10 19:30U:LGNDNews ReleaseHenlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene
2024-01-05 16:30U:LGNDNews ReleaseU.S. Food and Drug Administration Approves ZELSUVMI ¢ „ ¢ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum
2023-12-12 12:01U:LGNDNews ReleaseLigand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance
2023-12-12 09:00U:LGNDNews ReleaseSermonix Pharmaceuticals Shares Pharmacokinetic and Baseline Genomic Clinical Data Tied to ELAINE Lasofoxifene Trials of Patients With ESR1 Mutations
2023-12-06 16:02U:LGNDNews ReleaseLigand to Host Investor and Analyst Day on December 12, 2023 in New York City
2023-12-01 08:20U:LGNDNews ReleasePalvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN ¢ „ ¢ rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical Indications
2023-11-28 09:01U:LGNDNews ReleaseSermonix Pharmaceuticals Announces Five Abstracts Accepted for Presentation at 2023 San Antonio Breast Cancer Symposium
2023-11-08 16:01U:LGNDNews ReleaseLigand Reports Third Quarter 2023 Financial Results
2023-11-06 09:00U:LGNDNews ReleaseSermonix Pharmaceuticals Announces JCO Precision Oncology Publication of Case Report on a Complete Remission in a Metastatic Breast Cancer Patient Participating in ELAINE-1 Trial
2023-11-01 08:00U:LGNDNews ReleaseLigand Acquires Royalty on Sanofi ¢ € ™s TZIELD ‚ ® for $20 Million
2023-10-25 16:01U:LGNDNews ReleaseLigand To Report Third Quarter 2023 Financial Results On November 8
2023-10-18 08:00U:LGNDNews ReleaseOvid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid ¢ € ™s Cash Runway into 2026
2023-10-02 09:00U:LGNDNews ReleaseSermonix Pharmaceuticals Shares Results of EQUALS 2 Survey on Vaginal and Sexual Health in Patients with ER+/HER2- Metastatic Breast Cancer
2023-09-27 09:00U:LGNDNews ReleaseLigand Acquires Assets of Novan, Inc. for $12.2 Million
2023-09-26 17:05U:LGNDNews ReleaseLigand Appoints Martine Zimmermann to its Board of Directors
2023-09-22 09:00U:LGNDNews ReleaseLigand ¢ € ™s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze ‚ ® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
2023-09-21 09:20U:LGNDNews ReleaseLigand ¢ € ™s Partner Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI ‚ ® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control
2023-09-18 17:17U:LGNDNews ReleaseLigand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio
2023-09-01 22:02U:LGNDNews ReleaseLigand Pharmaceuticals Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
2023-08-08 16:01U:LGNDNews ReleaseLigand Reports Second Quarter 2023 Financial Results
2023-07-27 13:30U:LGNDNews ReleaseLigand ¢ € ™s Collaborator Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials
2023-07-25 16:30U:LGNDNews ReleaseLigand To Report Second Quarter 2023 Financial Results On August 8
2023-07-17 08:59U:LGNDNews ReleaseLigand Offers $15 Million to Acquire Assets of Novan, Inc.
2023-07-17 08:45U:LGNDNews ReleaseNovan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection
2023-06-29 09:00U:LGNDNews ReleaseSermonix Pharmaceuticals to Present Two Posters at The Menopause Society 2023 Annual Meeting
2023-06-05 09:01U:LGNDNews ReleaseSermonix Pharmaceuticals Shares ASCO Poster Presentation on Longer Patient Follow-up Results for ELAINE-2 Study in ESR1-mutated Metastatic Breast Cancer
2023-05-25 17:00U:LGNDNews ReleaseSermonix Pharmaceuticals to Share Longer Patient Follow-up Results for ELAINE-2 in Poster Presentation at ASCO 2023
2023-05-16 07:30U:LGNDNews ReleaseLigand ¢ € ™s Partner Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
2023-05-04 16:01U:LGNDNews ReleaseLigand Reports First Quarter 2023 Financial Results